Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Requirement of Hsp90 activity for IκB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-κB activation

Abstract

The molecular chaperone Hsp90 affects the function and fate of a number of signaling molecules. We have investigated the Hsp90 requirement for constitutive and inducible activity of the IκB kinase (IKK) complex and of NF-κB. Inhibition by the Hsp90 ATPase inhibitors, geldanamycin (GA) and radicicol (RC), revealed that Hsp90 controls IKKs at two levels, inducibility of enzymatic activity and biogenesis, which can be discriminated by short- and long-time GA incubation, respectively. Short-time inhibition of Hsp90 resulted in impaired IKK kinase activation by TNFα, IL-1β or phorbolester PMA. Furthermore, GA inhibited constitutive activation of IKK and NF-κB in Hodgkin's lymphoma cells. Hsp90 function was also required for trans- and autophosphorylation of transfected IKKβ. GA exposure for several hours resulted in a downmodulation of IKK complex α, β and γ subunits to various extent. Proteasome inhibition interfered with GA mediated IKK depletion and Hsp90 inhibition induced polyubiquitination of IKKα and β during protein synthesis. In fact, GA blocked biogenesis of IKKα and IKKβ but did not interfere with post-translational turnover. Together, these results define a dual requirement for Hsp90 as a regulator of NF-κB signaling by its general involvement in IKK activation and by its role in IKK homeostasis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P and Rosen N . (2002). J. Biol. Chem., 9, 9.

  • Bijlmakers MJ and Marsh M . (2000). Mol. Biol. Cell, 11, 1585–1595.

  • Byrd CA, Bornmann W, Erdjument-Bromage H, Tempst P, Pavletich N, Rosen N, Nathan CF and Ding A . (1999). Proc. Natl. Acad. Sci. USA, 96, 5645–5650.

  • Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV and Karin M . (2001). Cell, 107, 763–775.

  • Chakravortty D, Kato Y, Sugiyama T, Koide N, Mu MM, Yoshida T and Yokochi T . (2001). J. Immunol., 166, 2011–2017.

  • Chen G, Cao P and Goeddel DV . (2002). Mol. Cell, 9, 401–410.

  • Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, Li ZW, Karin M, Ware CF and Green DR . (2002). Immunity, 17, 525–535.

  • Devin A, Cook A, Lin Y, Rodriguez Y, Kelliher M and Liu Z . (2000). Immunity, 12, 419–429.

  • Emmerich F, Meiser M, Hummel M, Demel G, Foss HD, Jundt F, Mathas S, Krappmann D, Scheidereit C, Stein H and Dorken B . (1999). Blood, 94, 3129–3134.

  • Fisher DL, Mandart E and Doree M . (2000). EMBO J., 19, 1516–1524.

  • Ghosh S and Karin M . (2002). Cell, 109, S81–96.

  • Hatada EN, Krappmann D and Scheidereit C . (2000). Curr. Opin. Immunol., 12, 52–58.

  • Hohfeld J, Cyr DM and Patterson C . (2001). EMBO Rep., 2, 885–890.

  • Hsu H, Huang J, Shu HB, Baichwal V and Goeddel DV . (1996). Immunity, 4, 387–396.

  • Hu Y, Baud V, Oga T, Kim KI, Yoshida K and Karin M . (2001). Nature, 410, 710–714.

  • Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY and Karin M . (2000). J. Biol. Chem., 275, 36062–36066.

  • Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ and Leder P . (1998). Immunity, 8, 297–303.

  • Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B and Scheidereit C . (1999). Oncogene, 18, 943–953.

  • Lewis J, Devin A, Miller A, Lin Y, Rodriguez Y, Neckers L and Liu ZG . (2000). J. Biol. Chem., 275, 10519–10526.

  • Li Q and Verma IM . (2002). Nat. Rev. Immunol., 2, 725–734.

  • Maloney A and Workman P . (2002). Expert Opin. Biol. Ther., 2, 3–24.

  • Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F, Bommert K, Mechta-Grigoriou F, Stein H, Dorken B and Scheidereit C . (2002). EMBO J., 21, 4104–4113.

  • Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, Bommert K and Dorken B . (2003). Blood, 102, 1028–1034.

  • May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS and Ghosh S . (2000). Science, 289, 1550–1554.

  • Mordmuller B, Krappmann D, Esen M, Wegener E and Scheidereit C . (2003). EMBO Rep., 4, 82–87.

  • Poyet JL, Srinivasula SM, Lin JH, Fernandes-Alnemri T, Yamaoka S, Tsichlis PN and Alnemri ES . (2000). J. Biol. Chem., 275, 37966–37977.

  • Rayet B and Gelinas C . (1999). Oncogene, 18, 6938–6947.

  • Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC and Karin M . (2001). Science, 293, 1495–1499.

  • Shao J, Grammatikakis N, Scroggins BT, Uma S, Huang W, Chen JJ, Hartson SD and Matts RL . (2001). J. Biol. Chem., 276, 206–214.

  • Staudt LM . (2000). J. Exp. Med., 191, 207–212.

  • Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU and Pavletich NP . (1997). Cell, 89, 239–250.

  • Sugita T, Tanaka S, Murakami T, Miyoshi H and Ohnuki T . (1999). Biochem. Mol. Biol. Int., 47, 587–595.

  • Tegethoff S, Behlke J and Scheidereit C . (2003). Mol. Cell. Biol., 23, 2029–2041.

  • Whitesell L, Mimnaugh EG, De Costa B, Myers CE and Neckers LM . (1994). Proc. Natl. Acad. Sci. USA, 91, 8324–8328.

  • Yilmaz ZB, Weih DS, Sivakumar V and Weih F . (2003). EMBO J., 22, 121–130.

  • Yorgin PD, Hartson SD, Fellah AM, Scroggins BT, Huang W, Katsanis E, Couchman JM, Matts RL and Whitesell L . (2000). J. Immunol., 164, 2915–2923.

  • Young JC, Moarefi I and Hartl FU . (2001). J. Cell. Biol., 154, 267–273.

  • Zhang SQ, Kovalenko A, Cantarella G and Wallach D . (2000). Immunity, 12, 301–311.

Download references

Acknowledgements

This work was supported in part by a grant from the Deutsche Forschungsgemeinschaft (Sche277/7) to CS.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Claus Scheidereit.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Broemer, M., Krappmann, D. & Scheidereit, C. Requirement of Hsp90 activity for IκB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-κB activation. Oncogene 23, 5378–5386 (2004). https://doi.org/10.1038/sj.onc.1207705

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207705

Keywords

This article is cited by

Search

Quick links